SPOTLIGHT: ImaRx switches development focus

It's the season for strategic alternatives in biotechnology. This time it's ImaRx Therapeutics' turn, which has changed its focus from developing its SonoLysis program--proprietary microbubbles and ultrasound to treat ischemic stroke--to concentrating on the commercial opportunities for urokinase product sales. In a release, the company explained that they would have needed to find new financing this year if they had stayed focused on the clinical development of SonoLysis. Now those charges could be borne by a "third party" drawn in by the strategic review. Release

Suggested Articles

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.

RA Capital 's 15-month old inaugural venture fund that has already seen 25% of its portfolio companies IPO or be acquired.